Disc Medicine, Inc. (IRON)
NASDAQ (NMS) NASDAQ (NMS) Primary 
LSE 
Disc Medicine stock soars: take profit or buy into strength?
Disc Medicine (IRON) shares ripped higher on Monday morning after the company's experimental blood-disorder treatment, bitopertin, delivered positive Phase 3 results. In its press release, management said the APOLLO clinical trial met every primary and secondary endpoint, strengthening the firm's case for another FDA submission.
Disc Medicine's Bitopertin Nails Phase III Endpoints, Eyes FDA Resubmission
Disc Medicine NASDAQ: IRON said its Phase III APOLLO trial of investigational bitopertin met both co-primary endpoints and all secondary endpoints in patients with erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), supporting the company's plan to resubmit a new drug application to the U.S. Food and Drug Administration by the end of the year.
Disc Medicine Stock Has Its Best Day Since 2022 as Drug Trial Revives FDA Approval Hopes
Disc Medicine plans to resubmit its blood-disorder drug for FDA approval by year-end after a late-stage trial met all its primary and secondary goals.
Disc Medicine surges 38% after bitopertin clears Phase 3 trial endpoints
Disc Medicine (NASDAQ:IRON), the clinical-stage biopharmaceutical company, surged 38% to $78.24 on Monday after its experimental drug bitopertin met every endpoint in a pivotal phase 3 trial. The APOLLO trial results strengthened the prospects for bitopertin as a treatment for erythropoietic protoporphyria (EPP), a rare disease that causes severe pain and skin reactions when patients are exposed to sunlight.
Ironveld shares jump 32% at 0.025p as processing plant hits sustained production
Shares in Ironveld PLC (AIM:IRON) jumped 32% to 0.025p after the mining developer said its processing plant had reached sustained production and secured strong commercial demand. Ironveld, an AIM-listed company producing strategic metals for mineral processing, said its dense media separation plant was now running continuously for 16 hours a day on a double shift.
Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic Outlook Transcript
Disc Medicine, Inc. (IRON) Discusses Clinical Updates on Bitopertin, Selcodebart, and DISC-3405 and Strategic Outlook Transcript
Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge
Disc Medicine advances therapies for serious blood disorders; a key insider recently trimmed their stake amid strong one-year share gains.
Disc Medicine, Inc. (IRON) Discusses FDA Complete Response Letter and Path Forward for Bitopertin Regulatory Approval Transcript
Disc Medicine, Inc. (IRON) Discusses FDA Complete Response Letter and Path Forward for Bitopertin Regulatory Approval Transcript
Wall Street Analysts Believe Disc Medicine, Inc. (IRON) Could Rally 48.62%: Here's is How to Trade
The consensus price target hints at a 48.6% upside potential for Disc Medicine, Inc. (IRON). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Disc Medicine, Inc. (IRON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Disc Medicine, Inc. (IRON) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Disc Medicine: RALLY-MF Data Validates Pipeline Optionality
Disc Medicine is well-capitalized, with over $800M in cash, ensuring operational runway through 2029 regardless of bitopertin's launch success. Bitopertin's NDA is submitted, aiming for accelerated FDA approval; if successful, IRON transitions from R&D to commercial stage with significant revenue potential. Phase 2 data for DISC-0974 in myelofibrosis show strong efficacy, especially in synergy with JAK inhibitors, expanding the addressable market and clinical utility.
Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript
Disc Medicine, Inc. (IRON) Discusses ASH Conference Data Updates and Portfolio Progress Including Anemia and Iron Restriction Programs Transcript
